The Influence of an Elevated Production of Extracellular Enveloped Virions of the Vaccinia Virus on Its Properties in Infected Mice

The modern approach to developing attenuated smallpox vaccines usually consists in targeted inactivation of vaccinia virus (VACV) virulence genes. In this work, we studied how an elevated production of extracellular enveloped virions (EEVs) and the route of mouse infection can influence the virulenc...

Full description

Saved in:
Bibliographic Details
Published inActanaturae Vol. 12; no. 4; pp. 120 - 132
Main Authors Shchelkunov, S. N., Yakubitskiy, S. N., Bauer, T. V., Sergeev, A. A., Kabanov, A. S., Bulichev, L. E., Yurganova, I. A., Odnoshevskiy, D. A., Kolosova, I. V., Pyankov, S. A., Taranov, O. S.
Format Journal Article
LanguageEnglish
Published Russia (Federation) A.I. Gordeyev 01.10.2020
Subjects
vaccine
smallpox
virulence
immunogenicity
Online AccessGet full text

Cover

Abstract The modern approach to developing attenuated smallpox vaccines usually consists in targeted inactivation of vaccinia virus (VACV) virulence genes. In this work, we studied how an elevated production of extracellular enveloped virions (EEVs) and the route of mouse infection can influence the virulence and immunogenicity of VACV. The research subject was the LIVP strain, which is used in Russia for smallpox vaccination. Two point mutations causing an elevated production of EEVs compared with the parental LIVP strain were inserted into the sequence of the VACV A34R gene. The created mutant LIVP-A34R strain showed lower neurovirulence in an intracerebral injection test and elevated antibody production in the intradermal injection method. This VACV variant can be a promising platform for developing an attenuated, highly immunogenic vaccine against smallpox and other orthopoxvirus infections. It can also be used as a vector for designing live-attenuated recombinant polyvalent vaccines against various infectious diseases.
AbstractList The modern approach to developing attenuated smallpox vaccines usually consists in targeted inactivation of vaccinia virus (VACV) virulence genes. In this work, we studied how an elevated production of extracellular enveloped virions (EEVs) and the route of mouse infection can influence the virulence and immunogenicity of VACV. The research subject was the LIVP strain, which is used in Russia for smallpox vaccination. Two point mutations causing an elevated production of EEVs compared with the parental LIVP strain were inserted into the sequence of the VACV A34R gene. The created mutant LIVP-A34R strain showed lower neurovirulence in an intracerebral injection test and elevated antibody production in the intradermal injection method. This VACV variant can be a promising platform for developing an attenuated, highly immunogenic vaccine against smallpox and other orthopoxvirus infections. It can also be used as a vector for designing live-attenuated recombinant polyvalent vaccines against various infectious diseases.
The modern approach to developing attenuated smallpox vaccines usually consists in targeted inactivation of vaccinia virus (VACV) virulence genes. In this work, we studied how an elevated production of extracellular enveloped virions (EEVs) and the route of mouse infection can influence the virulence and immunogenicity of VACV. The research subject was the LIVP strain, which is used in Russia for smallpox vaccination. Two point mutations causing an elevated production of EEVs compared with the parental LIVP strain were inserted into the sequence of the VACV A34R gene. The created mutant LIVP-A34R strain showed lower neurovirulence in an intracerebral injection test and elevated antibody production in the intradermal injection method. This VACV variant can be a promising platform for developing an attenuated, highly immunogenic vaccine against smallpox and other orthopoxvirus infections. It can also be used as a vector for designing live-attenuated recombinant polyvalent vaccines against various infectious diseases.The modern approach to developing attenuated smallpox vaccines usually consists in targeted inactivation of vaccinia virus (VACV) virulence genes. In this work, we studied how an elevated production of extracellular enveloped virions (EEVs) and the route of mouse infection can influence the virulence and immunogenicity of VACV. The research subject was the LIVP strain, which is used in Russia for smallpox vaccination. Two point mutations causing an elevated production of EEVs compared with the parental LIVP strain were inserted into the sequence of the VACV A34R gene. The created mutant LIVP-A34R strain showed lower neurovirulence in an intracerebral injection test and elevated antibody production in the intradermal injection method. This VACV variant can be a promising platform for developing an attenuated, highly immunogenic vaccine against smallpox and other orthopoxvirus infections. It can also be used as a vector for designing live-attenuated recombinant polyvalent vaccines against various infectious diseases.
The modern approach to developing attenuated smallpox vaccines usually consists in targeted inactivation of vaccinia virus (VACV) virulence genes. In this work, we studied how an elevated production of extracellular enveloped virions (EEVs) and the route of mouse infection can influence the virulence and immunogenicity of VACV. The research subject was the LIVP strain, which is used in Russia for smallpox vaccination. Two point mutations causing an elevated production of EEVs compared with the parental LIVP strain were inserted into the sequence of the VACV gene. The created mutant LIVP-A34R strain showed lower neurovirulence in an intracerebral injection test and elevated antibody production in the intradermal injection method. This VACV variant can be a promising platform for developing an attenuated, highly immunogenic vaccine against smallpox and other orthopoxvirus infections. It can also be used as a vector for designing live-attenuated recombinant polyvalent vaccines against various infectious diseases.
The modern approach to developing attenuated smallpox vaccines usually consists in targeted inactivation of vaccinia virus (VACV) virulence genes. In this work, we studied how an elevated production of extracellular enveloped virions (EEVs) and the route of mouse infection can influence the virulence and immunogenicity of VACV. The research subject was the LIVP strain, which is used in Russia for smallpox vaccination. Two point mutations causing an elevated production of EEVs compared with the parental LIVP strain were inserted into the sequence of the VACV A34R gene. The created mutant LIVP-A34R strain showed lower neurovirulence in an intracerebral injection test and elevated antibody production in the intradermal injection method. This VACV variant can be a promising platform for developing an attenuated, highly immunogenic vaccine against smallpox and other orthopoxvirus infections. It can also be used as a vector for designing live-attenuated recombinant polyvalent vaccines against various infectious diseases.
Author Odnoshevskiy, D. A.
Yurganova, I. A.
Yakubitskiy, S. N.
Shchelkunov, S. N.
Bulichev, L. E.
Sergeev, A. A.
Kolosova, I. V.
Bauer, T. V.
Pyankov, S. A.
Kabanov, A. S.
Taranov, O. S.
AuthorAffiliation State Research Center of Virology and Biotechnology VECTOR, Rospoterbnadzor, Novosibirsk region, Koltsovo, 630559 Russia
AuthorAffiliation_xml – name: State Research Center of Virology and Biotechnology VECTOR, Rospoterbnadzor, Novosibirsk region, Koltsovo, 630559 Russia
Author_xml – sequence: 1
  givenname: S. N.
  surname: Shchelkunov
  fullname: Shchelkunov, S. N.
– sequence: 2
  givenname: S. N.
  surname: Yakubitskiy
  fullname: Yakubitskiy, S. N.
– sequence: 3
  givenname: T. V.
  surname: Bauer
  fullname: Bauer, T. V.
– sequence: 4
  givenname: A. A.
  surname: Sergeev
  fullname: Sergeev, A. A.
– sequence: 5
  givenname: A. S.
  surname: Kabanov
  fullname: Kabanov, A. S.
– sequence: 6
  givenname: L. E.
  surname: Bulichev
  fullname: Bulichev, L. E.
– sequence: 7
  givenname: I. A.
  surname: Yurganova
  fullname: Yurganova, I. A.
– sequence: 8
  givenname: D. A.
  surname: Odnoshevskiy
  fullname: Odnoshevskiy, D. A.
– sequence: 9
  givenname: I. V.
  surname: Kolosova
  fullname: Kolosova, I. V.
– sequence: 10
  givenname: S. A.
  surname: Pyankov
  fullname: Pyankov, S. A.
– sequence: 11
  givenname: O. S.
  surname: Taranov
  fullname: Taranov, O. S.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33456984$$D View this record in MEDLINE/PubMed
BookMark eNp9UbtuFDEUdRGUhJAfSIGmpNngx4zHbpBQtMBKQVAkaa07nuvEaNZebM8Kan4cTx4oUODG0r3noXvOS3IQYkBCzhg9F1zS_i3YAgHKnADPGdU9PyDHnPbdSvGOHZHTnL_R-mTXUqYPyZEQbSe1ao_Jr6s7bDbBTTMGi010DYRmPeEeCo7N1xTH2RYfw7JZ_ygJLE7TPEFq1mGPU9xV1I1PFZEXSKlqN2CtDx6W-VynodmUvEjtMBWPufFhcUS7OHz2Fl-RFw6mjKeP_wm5_rC-uvi0uvzycXPx_nJlW8rLyknNnez00A1u0I7hOFgtHR8UEwJkh30rNVMtU1YCKAdMOKZBjHaQwyBHcULePeju5mGLo8VQ75nMLvktpJ8mgjd_b4K_M7dxb3pVs6O0Crx5FEjx-4y5mK3PSyAQMM7Z8LZXfc-F4hX6-rnXH5On5CtAPQBsijkndMb6AkvU1dpPhlFz36151q2577ZS-T_UJ_X_kH4DyMWw6A
CitedBy_id crossref_primary_10_32607_actanaturae_17872
crossref_primary_10_3390_v14071453
crossref_primary_10_15789_1563_0625_IPO_2203
crossref_primary_10_3390_v14112580
crossref_primary_10_3390_pathogens10030377
crossref_primary_10_3390_v13081631
ContentType Journal Article
Copyright Copyright ® 2020 National Research University Higher School of Economics.
Copyright ® 2020 National Research University Higher School of Economics. 2020
Copyright_xml – notice: Copyright ® 2020 National Research University Higher School of Economics.
– notice: Copyright ® 2020 National Research University Higher School of Economics. 2020
DBID AAYXX
CITATION
NPM
7X8
5PM
DOI 10.32607/actanaturae.10972
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
PubMed
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EndPage 132
ExternalDocumentID PMC7800600
33456984
10_32607_actanaturae_10972
Genre Journal Article
GroupedDBID 642
AAKDD
AAYXX
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
CITATION
EBS
EJD
HYE
KQ8
M48
PGMZT
RPM
VCL
VIT
ADRAZ
NPM
7X8
5PM
ID FETCH-LOGICAL-c402t-f692f659b5bfb9f1edbc96f2b8133a65e746918418c6aa8fa13f19a3dcb6bb6d3
IEDL.DBID M48
ISSN 2075-8251
IngestDate Thu Aug 21 17:58:30 EDT 2025
Fri Jul 11 11:32:34 EDT 2025
Thu Apr 03 06:56:18 EDT 2025
Thu Apr 24 23:06:57 EDT 2025
Tue Jul 01 01:49:40 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 4
Keywords vaccine
smallpox
virulence
immunogenicity
Language English
License https://creativecommons.org/licenses/by-nc-nd/4.0
Copyright ® 2020 National Research University Higher School of Economics.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c402t-f692f659b5bfb9f1edbc96f2b8133a65e746918418c6aa8fa13f19a3dcb6bb6d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.32607/actanaturae.10972
PMID 33456984
PQID 2478772382
PQPubID 23479
PageCount 13
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7800600
proquest_miscellaneous_2478772382
pubmed_primary_33456984
crossref_citationtrail_10_32607_actanaturae_10972
crossref_primary_10_32607_actanaturae_10972
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-10-01
PublicationDateYYYYMMDD 2020-10-01
PublicationDate_xml – month: 10
  year: 2020
  text: 2020-10-01
  day: 01
PublicationDecade 2020
PublicationPlace Russia (Federation)
PublicationPlace_xml – name: Russia (Federation)
PublicationTitle Actanaturae
PublicationTitleAlternate Acta Naturae
PublicationYear 2020
Publisher A.I. Gordeyev
Publisher_xml – name: A.I. Gordeyev
SSID ssj0000654019
Score 2.1850326
Snippet The modern approach to developing attenuated smallpox vaccines usually consists in targeted inactivation of vaccinia virus (VACV) virulence genes. In this...
The modern approach to developing attenuated smallpox vaccines usually consists in targeted inactivation of vaccinia virus (VACV) virulence genes. In this...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 120
Title The Influence of an Elevated Production of Extracellular Enveloped Virions of the Vaccinia Virus on Its Properties in Infected Mice
URI https://www.ncbi.nlm.nih.gov/pubmed/33456984
https://www.proquest.com/docview/2478772382
https://pubmed.ncbi.nlm.nih.gov/PMC7800600
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1NT9wwELUQCKmXivLRbluQkXqrQjdO4sQHhBBaBEiLeugibtHYsdVIKy_dDwTn_nFmnOyK5UvimkycyOPY7zmT9xj7kSotRaXTyCmLBCU1EBUyLiIAoUEjolVBp7t_Kc8G6cV1dr3C5nZHbQdOXqR25Cc1GA8P7v7dH-ELf0iME-F4_gsMAinSwQQbJBlxSl7DlSknR4N-C_ebmRnxSfD6ELhSRvTXZvMfzSvNLK9VzwDo0zrKRwvT6Qb72CJKftwMgU9sxfpNtt54TN5vsf84EPj53IqEjxwHz3tDe4sgs-K_G8FXTA6d6d3hDWgrn2pTec-HeiKMuqrHNDopBPEivwJjal8DHZ_hUc_PpxNq6oaKtO2E157uiFMpXtvHmWibDU57f07OotZ5ITLIJ6eRk0o4mSmdaaeVi22ljZJO6AIpLcjM5siqkRvGhZEAhYM4cbGCpDJaai2rZIet-pG3Xxh3SEhAdK10hU5T0JClViZd5QRAbrtxh8XzPi5NK0tO7hjDEulJyEv5KC_hg7nosJ-La24aUY43o_fnqSvx3aFeBG9Hs0kpSJmIXNcw5nOTykV7SYLQUhVph-VLSV4EkC738hlf_w363HlBKjfdr-96ym_sgyAqH-oEv7PV6XhmdxHvTPVeGMR7YSPqAfbHBfg
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Influence+of+an+Elevated+Production+of+Extracellular+Enveloped+Virions+of+the+Vaccinia+Virus+on+Its+Properties+in+Infected+Mice&rft.jtitle=Actanaturae&rft.au=Shchelkunov%2C+S.+N.&rft.au=Yakubitskiy%2C+S.+N.&rft.au=Bauer%2C+T.+V.&rft.au=Sergeev%2C+A.+A.&rft.date=2020-10-01&rft.issn=2075-8251&rft.volume=12&rft.issue=4&rft.spage=120&rft.epage=132&rft_id=info:doi/10.32607%2Factanaturae.10972&rft.externalDBID=n%2Fa&rft.externalDocID=10_32607_actanaturae_10972
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2075-8251&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2075-8251&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2075-8251&client=summon